Linezolid Ascend Laboratories (Uk) (Linezolid)

Linezolid is an oxazolidinone antibiotic used to treat infections caused by resistant Gram‑positive bacteria.

• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: effective in eradicating the pathogen and resolving infection.
• Vancomycin‑resistant Enterococcus (VRE) infections: provides a therapeutic option where other agents fail.
• Community‑acquired bacterial pneumonia: helps clear pulmonary infection caused by susceptible organisms.
• Skin and soft‑tissue infections: reduces bacterial load and promotes healing of affected tissues.
• Complicated urinary tract infections: targets resistant Gram‑positive pathogens in the urinary system.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex and thereby blocking translation. This action is bacteriostatic against most susceptible organisms and bactericidal at higher concentrations, targeting Gram‑positive pathogens including MRSA and VRE. The binding is reversible and selective, sparing human mitochondrial ribosomes at therapeutic levels.

Linezolid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset commonly reported.
• Diarrhea: loose stools may occur during therapy.
• Headache: transient headache is frequently observed.
• Metallic taste: a distinctive taste sensation reported by some patients.
• Insomnia: occasional difficulty sleeping.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count requiring monitoring.
• Peripheral neuropathy: nerve damage presenting as tingling or numbness.
• Optic neuropathy: visual disturbances that may be irreversible.
• Serotonin syndrome: risk when combined with serotonergic agents.
• Lactic acidosis: rare metabolic complication.
• Severe anemia: marked reduction in hemoglobin levels.

Before initiating linezolid therapy, consider the following precautions.

• Renal or hepatic impairment: adjust monitoring as linezolid is metabolized hepatically and excreted renally.
• Concomitant serotonergic agents: risk of serotonin syndrome; avoid or monitor closely.
• Myelosuppression: monitor complete blood count during prolonged therapy.
• Pregnancy: category B; use only if benefit outweighs risk.
• Store below 25°C: keep in original packaging, protect from moisture.

Linezolid can interact with several drug classes; awareness of these interactions helps ensure safe use.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: risk of serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): increased risk of hypertensive crisis.
• Rifampin: reduces linezolid plasma concentrations, potentially decreasing efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: may increase INR; monitor coagulation parameters.
• Anticonvulsants (e.g., carbamazepine): may lower linezolid concentrations.
• Erythromycin: may increase linezolid levels, requiring dose adjustment.